Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Aduhelm (aducanumab-avwa)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

ADUHELM (aducanumab-avwa) (opens in a new tab)Original source URL: https://globalrph.com/dilution/aduhelm-aducanumab-avwa-injection/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/aduhelm-aducanumab-avwa-injection/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:45:43.109954+00:00
Source location
div.post-content
Packaged content SHA-256
139bcd8866317809a3fb02cde744a5681153f92c3e8e3f64200eac86ffb09a4f
Original response SHA-256
a935ace87d7302e5ab7b329dc9576792645dba750e9f4545e7e1a9f373fd262b
Source body SHA-256
717578106031c9c76cb7d13029c08ef13a5fe42673a7fd8b1e357660e32cc95d

ADUHELM™ (aducanumab-avwa) injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information (pdf)]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[ Calculated dose] [100 ml ] [60 minutes]

After an initial titration, the recommended dosage of ADUHELM is 10 mg/kg (see TABLE 1). ADUHELM is administered as an intravenous (IV) infusion over approximately one hour every four weeks and at least 21 days apart.

Table 1: Dosing Schedule
IV Infusion
(every 4 weeks)		 ADUHELM Dosage (administered over approximately one hour)
Infusion 1 and 2 1 mg/kg
Infusion 3 and 4 3 mg/kg
Infusion 5 and 6 6 mg/kg
Infusion 7 and beyond 10 mg/kg

Dilution Instructions
  • Use aseptic technique when preparing the ADUHELM diluted solution for intravenous infusion. Each vial is for single-dose only. Discard any unused portion.
  • Calculate the dose, total volume of ADUHELM solution required, and the number of vials needed based on the patient's actual body weight. Each vial contains an ADUHELM concentration of 100 mg per mL. More than one vial may be needed for a full dose.
  • Select the correct vial(s) for the required volume [see Dosage Forms and Strengths (3)].
  • Check that the ADUHELM solution is clear to opalescent and colorless to yellow solution. Do not use if opaque particles, discoloration, or other foreign particles are present.
  • Remove the flip-off cap from the vial. Insert the syringe needle into the vial through the center of the rubber stopper.
  • Withdraw the required volume of ADUHELM from the vial(s) and add to an infusion bag of 100 mL of 0.9% Sodium Chloride Injection, USP. Do not use other intravenous diluents to prepare the ADUHELM diluted solution.
  • Gently invert the infusion bag containing the ADUHELM diluted solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended. If not administered immediately, store the diluted solution of ADUHELM in 0.9% Sodium Chloride Injection, USP refrigerated at 2°C to 8°C (36°F to 46°F) for up to 3 days, or at room temperature up to 30°C (86°F) for up to 12 hours.
  • Prior to infusion, allow the ADUHELM diluted solution to warm to room temperature.
Administration Instructions
  • Visually inspect the ADUHELM diluted solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque or foreign particles are seen.
  • Infuse ADUHELM diluted solution intravenously over approximately one hour through an intravenous line containing a sterile, low-protein binding, 0.2 or 0.22 micron in-line filter.
  • Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity-type reaction

Description:
Aducanumab-avwa is a recombinant human immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, and is expressed in a Chinese hamster ovary cell line. Aducanumab-avwa has an approximate molecular weight of 146 kDa.

ADUHELM (aducanumab-avwa) injection is a preservative-free, sterile, clear to opalescent, and colorless to yellow solution for intravenous infusion after dilution supplied in single-dose vials available in concentrations of 170 mg/1.7 mL (100 mg/mL) or 300 mg/3 mL (100 mg/mL) of ADUHELM.

Each mL of solution contains 100 mg of aducanumab-avwa and L-arginine hydrochloride (31.60 mg), L-histidine (0.60 mg), L-histidine hydrochloride monohydrate (3.39 mg), L-methionine (1.49 mg), polysorbate 80 (0.50 mg), and Water for Injection at an approximate pH of 5.5.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Aducanumab-avwa is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. ADUHELM reduces amyloid beta plaques

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:

ADUHELM is indicated for the treatment of Alzheimer's disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).

CONTRAINDICATIONS Return to article top

Contraindications:

None.

WARNINGS AND PRECAUTIONS:
Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 8 doses of treatment with ADUHELM, particularly during titration. If a patient experiences symptoms which could be suggestive of ARIA, clinical evaluation should be performed, including MRI testing if indicated.

Hypersensitivity Reactions: Angioedema and urticaria have occurred. If a hypersensitivity reaction occurs, promptly discontinue the infusion of ADUHELM and initiate appropriate therapy.

Details: Drug information (pdf)

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

Most common adverse reactions (at least 10% and higher incidence compared to placebo): ARIA-Edema, headache, ARIA-H microhemorrhage, ARIA-H superficial siderosis, and fall.

To report SUSPECTED ADVERSE REACTIONS, contact Biogen at 1-833-425-9360 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug information (pdf)

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:
2.1 Dosing Instructions

After an initial titration, the recommended dosage of ADUHELM is 10 mg/kg (see TABLE 1). ADUHELM is administered as an intravenous (IV) infusion over approximately one hour every four weeks and at least 21 days apart.

Table 1: Dosing Schedule
IV Infusion
(every 4 weeks)		 ADUHELM Dosage (administered over approximately one hour)
Infusion 1 and 2 1 mg/kg
Infusion 3 and 4 3 mg/kg
Infusion 5 and 6 6 mg/kg
Infusion 7 and beyond 10 mg/kg
2.2 Monitoring for Amyloid Related Imaging Abnormalities

Obtain recent (within one year) brain magnetic resonance imaging (MRI) prior to initiating treatment. Obtain MRIs prior to the 7th infusion (first dose of 10 mg/kg) and 12th infusion (sixth dose of 10 mg/kg). If 10 or more new incident microhemorrhages or > 2 focal areas of superficial siderosis (radiographic severe ARIA-H) is observed, treatment may be continued with caution only after a clinical evaluation and a follow-up MRI demonstrates radiographic stabilization (i.e., no increase in size or number of ARIA-H) [see Warnings and Precautions (5.1)].

2.3 Resuming ADUHELM After Missed Dose

If an infusion is missed, resume administration at the same dose as soon as possible [see Dosage and Administration (2.1)]. Infusions are to be administered every 4 weeks and at least 21 days apart.

2.4 Dilution Instructions
  • Use aseptic technique when preparing the ADUHELM diluted solution for intravenous infusion. Each vial is for single-dose only. Discard any unused portion.
  • Calculate the dose, total volume of ADUHELM solution required, and the number of vials needed based on the patient's actual body weight. Each vial contains an ADUHELM concentration of 100 mg per mL. More than one vial may be needed for a full dose.
  • Select the correct vial(s) for the required volume [see Dosage Forms and Strengths (3)].
  • Check that the ADUHELM solution is clear to opalescent and colorless to yellow solution. Do not use if opaque particles, discoloration, or other foreign particles are present.
  • Remove the flip-off cap from the vial. Insert the syringe needle into the vial through the center of the rubber stopper.
  • Withdraw the required volume of ADUHELM from the vial(s) and add to an infusion bag of 100 mL of 0.9% Sodium Chloride Injection, USP. Do not use other intravenous diluents to prepare the ADUHELM diluted solution.
  • Gently invert the infusion bag containing the ADUHELM diluted solution to mix completely. Do not shake.
  • After dilution, immediate use is recommended. If not administered immediately, store the diluted solution of ADUHELM in 0.9% Sodium Chloride Injection, USP refrigerated at 2°C to 8°C (36°F to 46°F) for up to 3 days, or at room temperature up to 30°C (86°F) for up to 12 hours.
  • Prior to infusion, allow the ADUHELM diluted solution to warm to room temperature.
2.5 Administration Instructions
  • Visually inspect the ADUHELM diluted solution for particles or discoloration prior to administration. Do not use if it is discolored, or opaque or foreign particles are seen.
  • Infuse ADUHELM diluted solution intravenously over approximately one hour through an intravenous line containing a sterile, low-protein binding, 0.2 or 0.22 micron in-line filter.
  • Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity-type reaction

DOSAGE FORMS AND STRENGTHS:
ADUHELM is a clear to opalescent and colorless to yellow solution, available as:

Injection: 170 mg/1.7 mL (100 mg/mL) in a single-dose vial
Injection: 300 mg/3 mL (100 mg/mL) in a single-dose vial

Storage and Stability Return to article top

16.1 How Supplied

ADUHELM (aducanumab-avwa) injection is a preservative-free, sterile, clear to opalescent, and colorless to yellow solution. ADUHELM is supplied one vial per carton as follows:

170 mg/1.7 mL (100 mg/mL) single-dose vial (with red flip cap) - NDC 64406-101-01

300 mg/3 mL (100 mg/mL) single-dose vial (with blue flip cap) - NDC 64406-102-02

16.2 Storage and Handling

Unopened Vial

  • Store in original carton until use to protect from light.
  • Store in a refrigerator at 2°C to 8°C (36°F to 46°F).
  • Do not freeze or shake.
  • If no refrigeration is available, ADUHELM may be stored unopened in its original carton to protect from light at room temperature up to 25°C (77°F) for up to 3 days.
  • Prior to dilution, unopened vials of ADUHELM may be removed from and returned to the refrigerator if necessary, when kept in the original carton. Total combined time out of refrigeration with protection from light should not exceed 24 hours at room temperature up to 25°C (77°F).

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      aduhelm-aducanumab-avwa
      Source IDH51-99412AF6A556CC5F8525711E
      Generic name
      Aduhelm (aducanumab-avwa)
      Source IDH51-7387E743DDF28B5CF660632E
      Class
      Biologics and immunotherapy
      Source IDH51-F9D68D7C1F4B8C89785FF95C
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-93D56278398C6A73325A440C
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-61B2097DADCC8CF20050FEEF
      Mechanism
      Binds aggregated amyloid beta and promotes plaque clearance; current market availability must be confirmed.
      Source IDH51-97A4BF4B1BCDD18453ECDC28
      Mechanism level
      drug_specific
      Source IDH51-2ED6A97760D7803EB4661348
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-AB7E1E0D6B81653197465C77
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-51E0AA7BD20384FA6C1D9A0B
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-E7EF7790A75D5B6E12A9E73A
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-D2BC2D15D4079E2EA236FD28
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-6C2DD922517FDD9F12D5341E
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-56335624541B6E0E915ADC7A
      Legacy title
      Aduhelm (aducanumab-avwa)
      Source IDH51-0F711C9D007AF6ABDAAC236B
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-2331E0A5B082A4490DA919AE
      Search text
      Aduhelm (aducanumab-avwa) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Binds aggregated amyloid beta and promotes plaque clearance; current market availability must be confirmed. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-21119D79FCE5D0E75EE505E8
      Official access mode
      none
      Source IDH51-CC41F401E1088D7861D4ACD7
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-06A545B6BE577A4490B34F86

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-DAEBFC5E9D477C949434F80E
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-8A0F45218732A5321D8C9EF2
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-8904C12707EAF33B01A1A18A

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-DD95328384751F1E42B28B2F

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-74D47BBDD22632404EF25AFC
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      aduhelm-aducanumab-avwa
      Source IDH51-EC949F11819A5EC55D01F9B3
      Legacy title
      Aduhelm (aducanumab-avwa)
      Source IDH51-3A93328BF2AA48B1C3F9E1BA
      Generic name
      Aduhelm (aducanumab-avwa)
      Source IDH51-A3A194F9C42F5A6A10FFA035
      Class
      Biologics and immunotherapy
      Source IDH51-CAB70ACCA26699A1996AE706
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-06C9F459D933F1439EA5776B
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-52410195728CF4D6DE731606
      Populations
      1. Population not yet normalized
        Source IDH51-07094C7625D9C25654DD8B9B
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-A8622FDEE8626BFCFC3AB2CD
      High alert
      false
      Source IDH51-13DA85C2CBE4A97C7A8E38C6
      Hazardous
      false
      Source IDH51-0AB91EC02FF94A6610F5DFD8
      Status
      Legacy migration
      Source IDH51-E00A66FA03DCE6F9E6B5B255
      Version added
      Legacy
      Source IDH51-EE12F3A348A3736A8C292F67
      Sources
      LabelUrlKind
      Source IDH51-012A462C46789EFC6BD5F3A3
      GlobalRPh legacy IV dilution monograph
      Source IDH51-46BE1F1BBDA093F0C395E1B1
      		legacy:auto
      Source IDH51-A69D60CD799B97E76D1F6FC0
      		Legacy
      Source IDH51-623EB707AF0706A7080FFC89
      Clinical release verification
      Audit version
      3.4
      Source IDH51-73AC4DC1D8784195885CD707
      Audited on
      2026-08-30
      Source IDH51-9269BF1F6523BD37DF49B89D
      Level
      red
      Source IDH51-9B736B4581FE4E2FDF11B4C8
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-26FD291D8620E3CD4B47B3E4
      Exact current label candidate
      false
      Source IDH51-E77ADF789BF9D626959F1557
      Reference url count
      0
      Source IDH51-E56444DCEDD6BDCC34778535
      Broken reference count
      0
      Source IDH51-481FDCE1AE54C13E72740AFA
      Point of use confirmation required
      true
      Source IDH51-CEADA4FB3E1FD9C846453C35
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-861E370FD6AE26CFC2B71861

      Dosing source fields

      Id
      aduhelm-aducanumab-avwa
      Source IDH51-E4E29C74434C1EDBDE76D124
      Generic name
      Aduhelm (aducanumab-avwa)
      Source IDH51-C10D1F6D016588C2F007657D
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-6FD552A16BCC213FCF1ECC2A
      Package insert
      Query name
      Aduhelm
      Source IDH51-1FF87CD008EC46837ED81576
      Product and route must match
      true
      Source IDH51-026AB5D751AF7F7390D3C917
      Live current label enabled
      false
      Source IDH51-7CEEBF86191F4B3A66659BD9
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-ED88B3B1F7F3C28B42BFAA7D
      Direct official label access enabled
      true
      Source IDH51-F9D9E854EE7ADA6269552B1B
      Outbound server request required
      false
      Source IDH51-2062919960EBAAD1BF852CC9
      Local summary status
      not_bundled
      Source IDH51-CE024499484EDACCC81CB765
      Clinical review
      Locally normalized
      false
      Source IDH51-B135ACD9137F6C41A5EAB510
      Reviewed
      2026-08-29
      Source IDH51-BF4021B95350DBF55426E97F
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-15C68112ADD4DA5EA37D27CD
      Clinical release verification
      Audit version
      3.4
      Source IDH51-C4EAD67D272C6334B4A145B5
      Audited on
      2026-08-30
      Source IDH51-30CD34CDC6C94E94EC1B2A2F
      Level
      red
      Source IDH51-07940F77B99FB25404BE4F12
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-0FA42138BC2237EDE4311B45
      Exact current label candidate
      false
      Source IDH51-924608D63A338C64A2AE5B44
      Reference url count
      0
      Source IDH51-DD196984B4583680E7DD3257
      Broken reference count
      0
      Source IDH51-5244F1A4058FF049C8C2A48F
      Point of use confirmation required
      true
      Source IDH51-AD783253F8DA5A1E5C938729
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-FAA0767C9ADE42D4E488EC7F
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      aduhelm-aducanumab-avwa
      Source IDH51-0B6B6FFFA9CCB4958465895B
      Name
      Aduhelm (aducanumab-avwa)
      Source IDH51-C673B007A7761A54170F716D
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-A8E42EA12A70EC252BA2894C
      Review version
      3.1
      Source IDH51-1D5D6A7D43F768CADA500731
      Review date
      2026-08-30
      Source IDH51-8DC546870749D4E0B045B390
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-7DFDF0947851E8A9394EB435
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-13F9E1D94D0C050F27F9BC9F
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-EAAC538A0A29EFD2EC96370B
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-EB2473BBD2CC42E9002D83C1
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1203342F2A3CC8341789384E
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4C28BDCE0B915C802DB30BA0
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4446ECF3900081025CE62E42
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CB81FEDDF8EF36606674C145
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-FBB33E562E478DD6A35EBBE3
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-0E1EFA3A674E1CFA9DB521F2
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-628260752261193663D93185
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-48802B8C96B3B62C1A701354
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-CF30182315F37283AC77B8BF
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-EA39F75D8F4DE25FD5B504D7
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-EA6B626A8197D46990C7C364
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-EACE4A3D1EB8FD57CA271A02
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-3C731F37F656956EDF3007DF
      Adult dosing range
      Primary
      not_found
      Source IDH51-908CACC8B81032371DBEFBED
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-0A1E986B4C443290455498AA
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-97AF18952A0B79D16ABB7D0D
      Infusion time
      Primary
      not_found
      Source IDH51-C8F4996513EFDB78140F3441
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-B16F222448A38ACB1862D046
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-4DB77AD30E945C4DDE112C87
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-AC0DCCCC059661E730A2F509
      Guide generation allowed
      false
      Source IDH51-41B7C43D477E81AC2AC83B1E
      Pediatric
      Applicability
      not_established
      Source IDH51-668180E08549458A90BCB51D
      Guide generation allowed
      false
      Source IDH51-6D1CC3F5CB02F2191F92F591
      Neonatal
      Applicability
      not_established
      Source IDH51-8B3563AD268DA37D49058E7A
      Guide generation allowed
      false
      Source IDH51-346FC55D38A20C9F60985B1D
      Route presence
      Structured dilution
      false
      Source IDH51-1ACDB0AF73B5504F621576D3
      Iv push
      false
      Source IDH51-1E393FE2E821D81F93A5A2EA
      Continuous infusion
      false
      Source IDH51-E429FBA74BDA953BD4FDAC24
      Pediatric source
      false
      Source IDH51-552FAC6EB6B639EC7ACF85D3
      Neonatal source
      false
      Source IDH51-1C9F9367379D576A6EADC16C
      Legacy reference
      Status
      not_available
      Source IDH51-C05008DE4858FB1638D46E54
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-E03663A8429A738230365232
      Source files
      1. catalog.json
        Source IDH51-0D0F68865D4DD6F7F28FD592
      2. dosing.json
        Source IDH51-BCB386D2F79643A30C369E72
      3. legacy-map.json
        Source IDH51-5744AF158CE032C02E913A61
      4. review-queue.json
        Source IDH51-C18899011E5AA3DBA0BC092D
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-669E4FB99CBEF241DD93BB12
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-EC949F11819A5EC55D01F9B3catalog.json
      /records/7/id      		Historical; current review incomplete
      H51-3A93328BF2AA48B1C3F9E1BAcatalog.json
      /records/7/legacy_title      		Historical; current review incomplete
      H51-A3A194F9C42F5A6A10FFA035catalog.json
      /records/7/generic_name      		Historical; current review incomplete
      H51-CAB70ACCA26699A1996AE706catalog.json
      /records/7/class      		Historical; current review incomplete
      H51-06C9F459D933F1439EA5776Bcatalog.json
      /records/7/subclass      		Historical; current review incomplete
      H51-52410195728CF4D6DE731606catalog.json
      /records/7/summary      		Historical; current review incomplete
      H51-DD95328384751F1E42B28B2Fcatalog.json
      /records/7/warnings/0      		Historical; current review incomplete
      H51-74D47BBDD22632404EF25AFCcatalog.json
      /records/7/stability_notes/0      		Historical; current review incomplete
      H51-07094C7625D9C25654DD8B9Bcatalog.json
      /records/7/populations/0      		Historical; current review incomplete
      H51-A8622FDEE8626BFCFC3AB2CDcatalog.json
      /records/7/evidence_tier      		Historical; current review incomplete
      H51-13DA85C2CBE4A97C7A8E38C6catalog.json
      /records/7/high_alert      		Historical; current review incomplete
      H51-0AB91EC02FF94A6610F5DFD8catalog.json
      /records/7/hazardous      		Historical; current review incomplete
      H51-E00A66FA03DCE6F9E6B5B255catalog.json
      /records/7/status      		Historical; current review incomplete
      H51-6AE902C3B64999CFA7454043catalog.json
      /records/7/reviewed      		Historical; current review incomplete
      H51-EE12F3A348A3736A8C292F67catalog.json
      /records/7/version_added      		Historical; current review incomplete
      H51-012A462C46789EFC6BD5F3A3catalog.json
      /records/7/sources/0      		Historical; current review incomplete
      H51-46BE1F1BBDA093F0C395E1B1catalog.json
      /records/7/sources/0/label      		Historical; current review incomplete
      H51-A69D60CD799B97E76D1F6FC0catalog.json
      /records/7/sources/0/url      		Historical; current review incomplete
      H51-623EB707AF0706A7080FFC89catalog.json
      /records/7/sources/0/kind      		Historical; current review incomplete
      H51-73AC4DC1D8784195885CD707catalog.json
      /records/7/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-9269BF1F6523BD37DF49B89Dcatalog.json
      /records/7/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-9B736B4581FE4E2FDF11B4C8catalog.json
      /records/7/clinical_release_verification/level      		Historical; current review incomplete
      H51-26FD291D8620E3CD4B47B3E4catalog.json
      /records/7/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-E77ADF789BF9D626959F1557catalog.json
      /records/7/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-D8AD383E4C82B9D7D6D8EF0Ccatalog.json
      /records/7/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-45DEAA55D809128491CB8FC9catalog.json
      /records/7/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-81BE2543D4B55A3DDDC0B026catalog.json
      /records/7/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-E56444DCEDD6BDCC34778535catalog.json
      /records/7/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-481FDCE1AE54C13E72740AFAcatalog.json
      /records/7/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-CEADA4FB3E1FD9C846453C35catalog.json
      /records/7/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-861E370FD6AE26CFC2B71861catalog.json
      /records/7/clinical_release_verification/note      		Historical; current review incomplete
      H51-1727BC5636B87E41525820C6catalog.json
      /records/7/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-E4E29C74434C1EDBDE76D124dosing.json
      /records/7/id      		Historical; current review incomplete
      H51-C10D1F6D016588C2F007657Ddosing.json
      /records/7/generic_name      		Historical; current review incomplete
      H51-6FD552A16BCC213FCF1ECC2Adosing.json
      /records/7/coverage_status      		Historical; current review incomplete
      H51-1FF87CD008EC46837ED81576dosing.json
      /records/7/package_insert/query_name      		Historical; current review incomplete
      H51-115B5B1A1BB757A7BCE4C589dosing.json
      /records/7/package_insert/preferred_setid      		Historical; current review incomplete
      H51-026AB5D751AF7F7390D3C917dosing.json
      /records/7/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-7CEEBF86191F4B3A66659BD9dosing.json
      /records/7/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-ED88B3B1F7F3C28B42BFAA7Ddosing.json
      /records/7/package_insert/source_priority      		Historical; current review incomplete
      H51-F9D9E854EE7ADA6269552B1Bdosing.json
      /records/7/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-2062919960EBAAD1BF852CC9dosing.json
      /records/7/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-CE024499484EDACCC81CB765dosing.json
      /records/7/package_insert/local_summary_status      		Historical; current review incomplete
      H51-DAEBFC5E9D477C949434F80Edosing.json
      /records/7/renal/classification      		Historical; current review incomplete
      H51-8A0F45218732A5321D8C9EF2dosing.json
      /records/7/renal/summary      		Historical; current review incomplete
      H51-8904C12707EAF33B01A1A18Adosing.json
      /records/7/renal/method_note      		Historical; current review incomplete
      H51-B135ACD9137F6C41A5EAB510dosing.json
      /records/7/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-BF4021B95350DBF55426E97Fdosing.json
      /records/7/clinical_review/reviewed      		Historical; current review incomplete
      H51-15C68112ADD4DA5EA37D27CDdosing.json
      /records/7/clinical_review/status      		Historical; current review incomplete
      H51-C4EAD67D272C6334B4A145B5dosing.json
      /records/7/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-30CD34CDC6C94E94EC1B2A2Fdosing.json
      /records/7/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-07940F77B99FB25404BE4F12dosing.json
      /records/7/clinical_release_verification/level      		Historical; current review incomplete
      H51-0FA42138BC2237EDE4311B45dosing.json
      /records/7/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-924608D63A338C64A2AE5B44dosing.json
      /records/7/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-F36FB5A88D178072FC95F4D9dosing.json
      /records/7/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-03392472E67061F3B9E8D00Edosing.json
      /records/7/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-F811BCE22BB2BDA275FE1920dosing.json
      /records/7/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-DD196984B4583680E7DD3257dosing.json
      /records/7/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-5244F1A4058FF049C8C2A48Fdosing.json
      /records/7/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-AD783253F8DA5A1E5C938729dosing.json
      /records/7/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-FAA0767C9ADE42D4E488EC7Fdosing.json
      /records/7/clinical_release_verification/note      		Historical; current review incomplete
      H51-0E9C51CBE19E16A51C01DE98dosing.json
      /records/7/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-99412AF6A556CC5F8525711Efirst-look-v5.1.json
      /records/7/id      		Historical; current review incomplete
      H51-7387E743DDF28B5CF660632Efirst-look-v5.1.json
      /records/7/generic_name      		Historical; current review incomplete
      H51-F9D68D7C1F4B8C89785FF95Cfirst-look-v5.1.json
      /records/7/class      		Historical; current review incomplete
      H51-93D56278398C6A73325A440Cfirst-look-v5.1.json
      /records/7/subclass      		Historical; current review incomplete
      H51-61B2097DADCC8CF20050FEEFfirst-look-v5.1.json
      /records/7/primary_uses/0      		Historical; current review incomplete
      H51-97A4BF4B1BCDD18453ECDC28first-look-v5.1.json
      /records/7/mechanism      		Historical; current review incomplete
      H51-2ED6A97760D7803EB4661348first-look-v5.1.json
      /records/7/mechanism_level      		Historical; current review incomplete
      H51-AB7E1E0D6B81653197465C77first-look-v5.1.json
      /records/7/basic_dosing_orientation      		Historical; current review incomplete
      H51-51E0AA7BD20384FA6C1D9A0Bfirst-look-v5.1.json
      /records/7/administration_orientation      		Historical; current review incomplete
      H51-E7EF7790A75D5B6E12A9E73Afirst-look-v5.1.json
      /records/7/renal_and_population_orientation      		Historical; current review incomplete
      H51-D2BC2D15D4079E2EA236FD28first-look-v5.1.json
      /records/7/key_safety_orientation/0      		Historical; current review incomplete
      H51-6C2DD922517FDD9F12D5341Efirst-look-v5.1.json
      /records/7/coverage_path      		Historical; current review incomplete
      H51-56335624541B6E0E915ADC7Afirst-look-v5.1.json
      /records/7/coverage_path_label      		Historical; current review incomplete
      H51-12ECCCB003409B4F6E2AD93Efirst-look-v5.1.json
      /records/7/official_label_url      		Historical; current review incomplete
      H51-0F711C9D007AF6ABDAAC236Bfirst-look-v5.1.json
      /records/7/legacy_title      		Historical; current review incomplete
      H51-2331E0A5B082A4490DA919AEfirst-look-v5.1.json
      /records/7/review_note      		Historical; current review incomplete
      H51-21119D79FCE5D0E75EE505E8first-look-v5.1.json
      /records/7/search_text      		Historical; current review incomplete
      H51-61ED262F21E869C0AC67B475first-look-v5.1.json
      /records/7/official_search_url      		Historical; current review incomplete
      H51-CC41F401E1088D7861D4ACD7first-look-v5.1.json
      /records/7/official_access_mode      		Historical; current review incomplete
      H51-35020CF86AFA7CF14546376Efirst-look-v5.1.json
      /records/7/official_access_url      		Historical; current review incomplete
      H51-30091194DE73A622B87AE517first-look-v5.1.json
      /records/7/official_search_query      		Historical; current review incomplete
      H51-06A545B6BE577A4490B34F86first-look-v5.1.json
      /records/7/official_access_reason      		Historical; current review incomplete
      H51-0B6B6FFFA9CCB4958465895Bpreparation-assessments-v3.8.json
      /7/id      		Historical; current review incomplete
      H51-C673B007A7761A54170F716Dpreparation-assessments-v3.8.json
      /7/name      		Historical; current review incomplete
      H51-33E8699B2D6364A4C267C455preparation-assessments-v3.8.json
      /7/brands      		Historical; current review incomplete
      H51-A8E42EA12A70EC252BA2894Cpreparation-assessments-v3.8.json
      /7/therapeutic_class      		Historical; current review incomplete
      H51-1D5D6A7D43F768CADA500731preparation-assessments-v3.8.json
      /7/review_version      		Historical; current review incomplete
      H51-8DC546870749D4E0B045B390preparation-assessments-v3.8.json
      /7/review_date      		Historical; current review incomplete
      H51-7DFDF0947851E8A9394EB435preparation-assessments-v3.8.json
      /7/release_status      		Historical; current review incomplete
      H51-13F9E1D94D0C050F27F9BC9Fpreparation-assessments-v3.8.json
      /7/market_status/status      		Historical; current review incomplete
      H51-EAAC538A0A29EFD2EC96370Bpreparation-assessments-v3.8.json
      /7/market_status/basis      		Historical; current review incomplete
      H51-EB2473BBD2CC42E9002D83C1preparation-assessments-v3.8.json
      /7/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-1203342F2A3CC8341789384Epreparation-assessments-v3.8.json
      /7/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-4C28BDCE0B915C802DB30BA0preparation-assessments-v3.8.json
      /7/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-4446ECF3900081025CE62E42preparation-assessments-v3.8.json
      /7/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-CB81FEDDF8EF36606674C145preparation-assessments-v3.8.json
      /7/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-FBB33E562E478DD6A35EBBE3preparation-assessments-v3.8.json
      /7/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-0E1EFA3A674E1CFA9DB521F2preparation-assessments-v3.8.json
      /7/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-628260752261193663D93185preparation-assessments-v3.8.json
      /7/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-48802B8C96B3B62C1A701354preparation-assessments-v3.8.json
      /7/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-6BCE93409EC6B9C9E81E379Dpreparation-assessments-v3.8.json
      /7/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-5395AAF0FD53CBF053D281B6preparation-assessments-v3.8.json
      /7/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-70FCC1096A8E9EF87841518Fpreparation-assessments-v3.8.json
      /7/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-F1D8C0E8D574A1802EAD8F34preparation-assessments-v3.8.json
      /7/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-CF30182315F37283AC77B8BFpreparation-assessments-v3.8.json
      /7/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-CCDA157F39C2B045FC02FE5Epreparation-assessments-v3.8.json
      /7/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-EA39F75D8F4DE25FD5B504D7preparation-assessments-v3.8.json
      /7/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-EA6B626A8197D46990C7C364preparation-assessments-v3.8.json
      /7/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-EACE4A3D1EB8FD57CA271A02preparation-assessments-v3.8.json
      /7/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-3C731F37F656956EDF3007DFpreparation-assessments-v3.8.json
      /7/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-908CACC8B81032371DBEFBEDpreparation-assessments-v3.8.json
      /7/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-0A1E986B4C443290455498AApreparation-assessments-v3.8.json
      /7/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-97AF18952A0B79D16ABB7D0Dpreparation-assessments-v3.8.json
      /7/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-C8F4996513EFDB78140F3441preparation-assessments-v3.8.json
      /7/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-B16F222448A38ACB1862D046preparation-assessments-v3.8.json
      /7/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-4DB77AD30E945C4DDE112C87preparation-assessments-v3.8.json
      /7/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-AC0DCCCC059661E730A2F509preparation-assessments-v3.8.json
      /7/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-41B7C43D477E81AC2AC83B1Epreparation-assessments-v3.8.json
      /7/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-668180E08549458A90BCB51Dpreparation-assessments-v3.8.json
      /7/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-6D1CC3F5CB02F2191F92F591preparation-assessments-v3.8.json
      /7/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-8B3563AD268DA37D49058E7Apreparation-assessments-v3.8.json
      /7/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-346FC55D38A20C9F60985B1Dpreparation-assessments-v3.8.json
      /7/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-1ACDB0AF73B5504F621576D3preparation-assessments-v3.8.json
      /7/route_presence/structured_dilution      		Historical; current review incomplete
      H51-1E393FE2E821D81F93A5A2EApreparation-assessments-v3.8.json
      /7/route_presence/iv_push      		Historical; current review incomplete
      H51-E429FBA74BDA953BD4FDAC24preparation-assessments-v3.8.json
      /7/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-552FAC6EB6B639EC7ACF85D3preparation-assessments-v3.8.json
      /7/route_presence/pediatric_source      		Historical; current review incomplete
      H51-1C9F9367379D576A6EADC16Cpreparation-assessments-v3.8.json
      /7/route_presence/neonatal_source      		Historical; current review incomplete
      H51-C05008DE4858FB1638D46E54preparation-assessments-v3.8.json
      /7/legacy_reference/status      		Historical; current review incomplete
      H51-E03663A8429A738230365232preparation-assessments-v3.8.json
      /7/label_resolution/status      		Historical; current review incomplete
      H51-0D0F68865D4DD6F7F28FD592preparation-assessments-v3.8.json
      /7/source_files/0      		Historical; current review incomplete
      H51-BCB386D2F79643A30C369E72preparation-assessments-v3.8.json
      /7/source_files/1      		Historical; current review incomplete
      H51-5744AF158CE032C02E913A61preparation-assessments-v3.8.json
      /7/source_files/2      		Historical; current review incomplete
      H51-C18899011E5AA3DBA0BC092Dpreparation-assessments-v3.8.json
      /7/source_files/3      		Historical; current review incomplete
      H51-669E4FB99CBEF241DD93BB12preparation-assessments-v3.8.json
      /7/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top